Food and Drug Administration (FDA)
NEWS
Gotham Therapeutics launched in New York with a $54 million Series A financing. The focus is on a subgroup of RNA metabolism called epitranscriptomics. This involves the biochemical modifications of RNA within a cell, which have an impact on gene expression.
Although race is thought of as a social concept, ‘there’s growing evidence that, whether for environmental or genetic reasons, drugs may have different effects on different populations.’
MeiraGTx, headquartered in London, UK, acquired Vector Neurosciences in an all-stock deal. As part of the deal, MeiraGTx picks up Vector’s Phase II gene therapy program for Parkinson’s disease.
FDA issued a Complete Response letter to Acacia Pharma on Friday 5 October
Application Seeks Accelerated Approval for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma
Bristol-Myers Squibb, Nektar Therapeutics, Amgen and others will be recognized for their significant contributions to the California life sciences industry during the November 2018 Pantheon DiNA Awards hosted by the California Life Sciences Association.
A study published in the Annals of Internal Medicine highlights some of the problems that drug shortages bring to the healthcare system, including a rise in prices. The research, as highlighted by Business Insider, examined the prices of 917 drugs that were in shortage between 2015 and 2016.
Swiss pharma giant Novartis could be on its way to securing regulatory approval for its secondary progressive multiple sclerosis (SPMS) treatment siponimod.
Seattle Genetics and its development partner Takeda recently announced stellar Phase III data from its ECHELON-2 clinical trial of Adcetris for peripheral T-cell lymphoma. Clay Siegall, president and CEO of Seattle Genetics, took time to speak with BioSpace about the approval and plans for the drug.
JOBS
IN THE PRESS